Omaveloxolone capsules, 2.5 mg + omaveloxolone capsules, 5 mg + omaveloxolone capsules, 10 mg + Placebo capsules + omaveloxolone capsules, 20 mg + omaveloxolone capsules, 40 mg + omaveloxolone capsules, 80 mg + omaveloxolone capsules, 160 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
MItochondrial Myopathies
Conditions
MItochondrial Myopathies
Trial Timeline
May 5, 2015 → Nov 30, 2017
NCT ID
NCT02255422About Omaveloxolone capsules, 2.5 mg + omaveloxolone capsules, 5 mg + omaveloxolone capsules, 10 mg + Placebo capsules + omaveloxolone capsules, 20 mg + omaveloxolone capsules, 40 mg + omaveloxolone capsules, 80 mg + omaveloxolone capsules, 160 mg
Omaveloxolone capsules, 2.5 mg + omaveloxolone capsules, 5 mg + omaveloxolone capsules, 10 mg + Placebo capsules + omaveloxolone capsules, 20 mg + omaveloxolone capsules, 40 mg + omaveloxolone capsules, 80 mg + omaveloxolone capsules, 160 mg is a phase 2 stage product being developed by AbbVie for MItochondrial Myopathies. The current trial status is completed. This product is registered under clinical trial identifier NCT02255422. Target conditions include MItochondrial Myopathies.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02255422 | Phase 2 | Completed |
Competing Products
13 competing products in MItochondrial Myopathies
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| REN001 | OnKure Therapeutics | Phase 1 | 25 |
| Mavodelpar + Placebo | OnKure Therapeutics | Phase 2 | 44 |
| REN001 | OnKure Therapeutics | Phase 2/3 | 57 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 2 | 52 |
| Cysteamine Bitartrate | Amgen | Phase 2 | 51 |
| Cysteamine Bitartrate | Amgen | Phase 2 | 51 |
| Vatiquinone | PTC Therapeutics | Phase 2/3 | 62 |
| EPI-743 | PTC Therapeutics | Pre-clinical | 20 |
| RG2133 (2',3',5'-tri-O-acetyluridine) | Repligen | Phase 1 | 30 |
| Vatiquinone | PTC Therapeutics | Pre-clinical | 20 |
| Vatiquinone | PTC Therapeutics | Phase 3 | 74 |
| Oral administration of 100 mg KH176 twice daily | Certara | Phase 2 | 47 |
| Sonlicromanol + Placebo | Certara | Phase 2 | 47 |